LTI 2355
Alternative Names: LTI-2355Latest Information Update: 30 May 2025
At a glance
- Originator Rein Therapeutics
- Class Anti-inflammatories; Antifibrotics; Peptides; Peptidomimetics
- Mechanism of Action Phagocyte modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Post acute COVID 19 syndrome; Pulmonary fibrosis
Most Recent Events
- 15 Apr 2025 Preclinical trials in Post-acute-COVID-19-syndrome in USA (unspecified route), prior to April 2025
- 15 Apr 2025 Preclinical trials in Pulmonary fibrosis in USA (unspecified route), prior to April 2025
- 15 Apr 2025 Pharmacodynamics data from a Pulmonary fibrosis and Post-acute-COVID-19-syndrome released by Rein Therapeutics